NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. SLS (“SELLAS” or the “Company”), a late-stage biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced its formation Poster presentation in connection with its highly selective CDK9 inhibitor GFH009 at the Tenth Annual Society of Hematologic Oncology (SOHO) Meetings being held September 28-October 1, 2022 in Houston, Texas and virtually.
The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.
See more presentation details below:
Title: “Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague-Dawley Rats”
Abstract #: AML-259
Appointment time: Wednesday, September 28, 2022 at 6:05 p.m. ET
Moderator: Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. SLS is a late-stage clinical-stage biopharmaceutical company focused on the development of novel therapeutics across a broad spectrum of cancer indications. SELLAS’ lead product candidate, Galinpepimut-S (GPS), licensed from Memorial Sloan Kettering Cancer Center, targets the WT1 protein, which is present in a number of tumor types. GPS, as monotherapy or in combination with other therapies, has the potential to treat a wide range of hematological malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor licensed from GenFleet Therapeutics (Shanghai), Inc. for all therapeutic and diagnostic uses in the world outside of Greater China.
You can find more information about SELLAS at www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are…
